 |
|
|
 |
Correction Furst DE. Window of opportunity [editorial]. J Rheumatol 2004;31:1677-9. The first paragraphs, page 1677, should appear as follows: "...In this analogy, our present-day medications would not be as effective given later as given early; this time period of greatest effectiveness is the window of opportunity. And when considering the opening of a window of opportunity, one must also consider the concept of closing such a window. First, do the data demonstrate that treating at an early point after RA begins is more effective than treating later?..." Within paragraph 3 on page 1677, at line 10, the text should read as follows: "...Borg, et al, in a double-blind, randomized study, treated patients with < 2 years' disease with auranofin or placebo and followed patients for 24 months. An average 8 month delay in starting auranofin was still discernible as more [not less] joint swelling and more [not less] radiographic progression at 24 months6." We regret the errors.
|